Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Human Genome Sciences Inc | 894 |
| 2 | University of California, San Diego | 498 |
| 3 | Massachusetts Institute of Technology | 464 |
| 4 | AbbVie Inc | 421 |
| 5 | Bristol Myers Squibb Co | 419 |
| 6 | Allergan Inc | 410 |
| 7 | BASF SE | 341 |
| 8 | Harvard University | 335 |
| 9 | Bayer AG | 322 |
| 10 | Novartis AG | 259 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 38,128 |
| 2 | A61P | Therapeutic activity (drug indications) | 34,216 |
| 3 | C07K | Peptides | 11,915 |
| 4 | C12N | Microorganisms, enzymes | 10,564 |
| 5 | C07D | Heterocyclic compounds | 10,213 |
| 6 | Y02A | Climate change adaptation | 8,230 |
| 7 | G01N | Investigating / analysing materials | 5,105 |
| 8 | A61L | Sterilising / disinfecting materials | 4,411 |
| 9 | C12Q | Measuring/testing involving enzymes | 3,972 |
| 10 | A01N | Preservation of bodies; biocides; pest repellents | 3,613 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Palatable trimethoprim oral solution | 1997 | Avadel Pharmaceuticals USA Inc | 26 |
| Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use | 1994 | Alcon Cusi SA | 25 |
| Tablets comprising trimethoprim and a sulfonamide | 1986 | Astellas Pharma Europe BV | 13 |
| Solution containing trimethoprim, sulfacetamide and polymyxin | 1976 | SmithKline Beecham Corp | 13 |
| Tablets containing trimethoprim, sulphamethoxazole and polyvinylpyrrolidone | 1981 | DDSA PHARMACEUTICALS | 12 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Pneumocystis jirovecii pneumonia detection and treatment | 42 |
| 2 | Urinary Tract Infections Management | 28 |
| 3 | Antibiotic Resistance in Bacteria | 20 |
| 4 | Antibiotics Pharmacokinetics and Efficacy | 11 |
| 5 | Neutropenia and Cancer Infections | 8 |
| 6 | Pneumonia and Respiratory Infections | 8 |
| 7 | Actinomycetales infections and treatment | 7 |
| 8 | Antimicrobial Resistance in Staphylococcus | 7 |
| 9 | Drug-Induced Adverse Reactions | 7 |
| 10 | HIV/AIDS Research and Interventions | 7 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Sherry F. Queener | Indiana University – Purdue University Indianapolis | 42 |
| 2 | Aleem Gangjee | Duquesne University | 27 |
| 3 | Rudolf Then | Roche (Switzerland) | 14 |
| 4 | Allan Ronald | University of Manitoba | 13 |
| 5 | R. N. Grüneberg | University College London | 13 |
| 6 | S. G. B. Amyes | University of London | 12 |
| 7 | J. Feeney | National Institute for Medical Research | 11 |
| 8 | W. Brumfitt | University College London | 11 |
| 9 | Anil Vasudevan | Duquesne University | 5 |
| 10 | J. M. T. Hamilton‐Miller | University College London | 10 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Projections of Global Mortality and Burden of Disease from 2002 to 2030 | 2006 | 11534 | Global Maternal and Child Health |
| A computational procedure for determining energetically favorable binding sites on biologically important macromolecules | 1985 | 2642 | Protein Structure and Dynamics |
| Structure and energetics of ligand binding to proteins: <i>Escherichia coli</i> dihydrofolate reductase‐trimethoprim, a drug‐receptor system | 1988 | 2063 | Protein Structure and Dynamics |
| Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis | 2002 | 961 | Liver Disease and Transplantation |
| <i>Pneumocystis carinii</i> Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other Immunodeficiencies | 1984 | 857 | HIV/AIDS drug development and treatment |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of trimethoprim?
Which research topics are most associated with trimethoprim in the scientific literature?
What are the leading assignees in trimethoprim-related patents?
What is a notable patent application for trimethoprim formulations?
Which leading researcher has published extensively on trimethoprim?